Biocon reports Q2FY25 revenue of Rs 3,623cr amid generics pressure
Biocon Limited, a leading global biopharmaceutical company, released its consolidated financial results for Q2FY25, reporting a total revenue of Rs 3,623 crore. This represented a ... Read More
Biocon Biologics wraps up $3.3bn acquisition of Viatris biosimilars unit
Biocon said that its subsidiary Biocon Biologics has wrapped up the previously announced $3.3 billion acquisition of the biosimilars business of US-based pharma company Viatris. ... Read More
Biocon to sell 15% stake in Biocon Biologics to Serum Institute of India
Biocon has agreed to divest a stake of around 15% in its subsidiary — Biocon Biologics Limited (BBL) to Serum Institute Life Sciences Private Limited ... Read More
Biocon gets license for Adagio Therapeutics’ ADG20 for Covid-19 treatment
Biocon Limited said that its subsidiary Biocon Biologics has been given an exclusive license from Adagio Therapeutics, a US-based biotech company, for manufacturing and commercializing ... Read More